Breaking News, Collaborations & Alliances

Secarna, Evotec Expand Strategic Antisense Discovery Pact

To discover, research and develop programs leveraging Secarna’s antisense oligonucleotide expertise with Evotec’s discovery and development capabilities.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Secarna Pharmaceuticals, a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide (ASO) therapies, and Evotec SE, have expanded their strategic partnership in the field of ASO-based therapeutics. The companies initiated joint work on third-party discovery, research and development programs leveraging Secarna’s antisense oligonucleotide expertise via its LNAplus platform with Evotec’s discovery and development capabilities.   Across ther...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters